Literature DB >> 19022314

Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.

Peter B Gilbert1, Alicia Sato, Xiao Sun, Devan V Mehrotra.   

Abstract

In randomized clinical trials designed to compare the magnitude of vaccine-induced immune responses between vaccination regimens, the statistical method used for the analysis typically does not account for baseline participant characteristics. This article shows that incorporating baseline variables predictive of the immunogenicity study endpoint can provide large gains in precision and power for estimation and testing of the group mean difference (requiring fewer subjects for the same scientific output) compared to conventional methods, and recommends the "semiparametric efficient" method described in Tsiatis et al. [Tsiatis AA, Davidian M, Zhang M, Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med 2007. doi:10.1002/sim.3113] for practical use. As such, vaccine clinical trial programs can be improved (1) by investigating baseline predictors (e.g., readouts from laboratory assays) of vaccine-induced immune responses, and (2) by implementing the proposed semiparametric efficient method in trials where baseline predictors are available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022314      PMCID: PMC2653280          DOI: 10.1016/j.vaccine.2008.10.083

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data.

Authors:  Marie Davidian; Anastasios A Tsiatis; Selene Leon
Journal:  Stat Sci       Date:  2005-08       Impact factor: 2.901

2.  Uses and abuses of analysis of covariance in clinical trials.

Authors:  M J Egger; M L Coleman; J R Ward; J C Reading; H J Williams
Journal:  Control Clin Trials       Date:  1985-03

3.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

4.  Improving efficiency of inferences in randomized clinical trials using auxiliary covariates.

Authors:  Min Zhang; Anastasios A Tsiatis; Marie Davidian
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

  4 in total
  7 in total

1.  On the covariate-adjusted estimation for an overall treatment difference with data from a randomized comparative clinical trial.

Authors:  Lu Tian; Tianxi Cai; Lihui Zhao; Lee-Jen Wei
Journal:  Biostatistics       Date:  2012-01-30       Impact factor: 5.899

2.  Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials.

Authors:  Peter B Gilbert; Xuesong Yu; Andrea Rotnitzky
Journal:  Stat Med       Date:  2013-10-09       Impact factor: 2.373

Review 3.  Recent developments in clinical trial designs for HIV vaccine research.

Authors:  Laura Richert; Edouard Lhomme; Catherine Fagard; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Variable selection for covariate-adjusted semiparametric inference in randomized clinical trials.

Authors:  Shuai Yuan; Hao Helen Zhang; Marie Davidian
Journal:  Stat Med       Date:  2012-06-26       Impact factor: 2.373

5.  Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.

Authors:  Yunda Huang; Lily Zhang; Holly Janes; Nicole Frahm; Abby Isaacs; Jerome H Kim; David Montefiori; M Julie McElrath; Georgia D Tomaras; Peter B Gilbert
Journal:  Vaccine       Date:  2017-01-25       Impact factor: 3.641

6.  HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

Authors:  Tomer Hertz; Hasan Ahmed; David P Friedrich; Danilo R Casimiro; Steven G Self; Lawrence Corey; M Juliana McElrath; Susan Buchbinder; Helen Horton; Nicole Frahm; Michael N Robertson; Barney S Graham; Peter Gilbert
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823

7.  Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells.

Authors:  Leigh Fisher; Melissa Zinter; Sherry Stanfield-Oakley; Lindsay N Carpp; R Whitney Edwards; Thomas Denny; Zoe Moodie; Fatima Laher; Linda-Gail Bekker; M Juliana McElrath; Peter B Gilbert; Lawrence Corey; Georgia Tomaras; Justin Pollara; Guido Ferrari
Journal:  Front Immunol       Date:  2019-11-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.